Dermapharm Holding Future Growth
Future criteria checks 1/6
Dermapharm Holding is forecast to grow earnings and revenue by 1.2% and 5.2% per annum respectively. EPS is expected to grow by 1.2% per annum. Return on equity is forecast to be 29.7% in 3 years.
Key information
1.2%
Earnings growth rate
1.2%
EPS growth rate
Pharmaceuticals earnings growth | 23.9% |
Revenue growth rate | 5.2% |
Future return on equity | 29.7% |
Analyst coverage | Low |
Last updated | 01 Mar 2023 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 1,225 | N/A | 237 | N/A | 2 |
12/31/2024 | 1,215 | 190 | 186 | 231 | 4 |
12/31/2023 | 1,187 | 186 | 171 | 220 | 4 |
12/31/2022 | 1,038 | 188 | 199 | 247 | 5 |
9/30/2022 | 1,024 | 176 | 222 | 269 | N/A |
6/30/2022 | 1,004 | 185 | 191 | 249 | N/A |
3/31/2022 | 980 | 211 | 190 | 252 | N/A |
12/31/2021 | 960 | 210 | 189 | 250 | N/A |
9/30/2021 | 902 | 162 | 153 | 209 | N/A |
6/30/2021 | 858 | 123 | 115 | 164 | N/A |
3/31/2021 | 828 | 95 | 96 | 139 | N/A |
12/31/2020 | 808 | 86 | 90 | 131 | N/A |
9/30/2020 | 775 | 80 | 60 | 104 | N/A |
6/30/2020 | 760 | 77 | 58 | 97 | N/A |
3/31/2020 | 743 | 85 | 69 | 114 | N/A |
12/31/2019 | 714 | 77 | 54 | 101 | N/A |
9/30/2019 | 674 | 73 | 51 | 90 | N/A |
6/30/2019 | 639 | 77 | 70 | 109 | N/A |
3/31/2019 | 611 | 73 | 84 | 115 | N/A |
12/31/2018 | 584 | 75 | 133 | 159 | N/A |
9/30/2018 | 558 | 75 | 143 | 165 | N/A |
6/30/2018 | 525 | 76 | 62 | 137 | N/A |
3/31/2018 | 498 | 79 | 45 | 120 | N/A |
12/31/2017 | 480 | 78 | 12 | 87 | N/A |
9/30/2017 | 486 | 84 | 8 | 84 | N/A |
12/31/2016 | 455 | 77 | 61 | 77 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DMPH.F's forecast earnings growth (1.2% per year) is below the savings rate (2.1%).
Earnings vs Market: DMPH.F's earnings (1.2% per year) are forecast to grow slower than the US market (14.9% per year).
High Growth Earnings: DMPH.F's earnings are forecast to grow, but not significantly.
Revenue vs Market: DMPH.F's revenue (5.2% per year) is forecast to grow slower than the US market (8.1% per year).
High Growth Revenue: DMPH.F's revenue (5.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DMPH.F's Return on Equity is forecast to be high in 3 years time (29.7%)